Evaluating a new eye drop for dry eye disease
Official title: A Phase 3, Randomized, Double-Masked, Vehicle-controlled, Multi-center Study Evaluating the Safety and Efficacy of 5% VVN001 in Chinese Subjects With Dry Eye Disease
Run by VivaVision Biotech, Inc · NCT06360133 · Data updated 2026-11-12
This study is testing a new eye drop for dry eye disease to see if it can help people aged 30 to 80 feel better and improve their eye health.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 30 Years to 80 Years |
| Sex | All |
| Enrollment | 700 (estimated) |
| Sponsor | VivaVision Biotech, Inc Industry-sponsored |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Status | Recruiting |
| Started | April 1, 2024 |
| Main results expected | April 30, 2027 |
| Study ends | April 30, 2027 |
| Registry record updated | August 20, 2026 |
| Trial ID | NCT06360133 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are Chinese individuals aged 30 to 80 with a history of dry eye disease who have been using artificial tears recently.
✕Probably not a fit
Patients with uncontrolled glaucoma or known hypersensitivity to the study medication will not benefit from this trial.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 3 clinical trial is a randomized, double-masked, vehicle-controlled study aimed at assessing the safety and efficacy of a 5% VVN001 Ophthalmic Solution in patients suffering from dry eye disease. Conducted in multiple centers, the trial will compare the new treatment against a placebo vehicle in Chinese subjects aged 30 to 80 who have a documented history of dry eye. Participants will be monitored for improvements in eye dryness symptoms and overall eye health throughout the study duration.
Why it matters
Potential benefit: If successful, this treatment could significantly alleviate symptoms of dry eye disease and improve patients' quality of life.
How similar studies have gone: Other studies have shown promise in treating dry eye disease with similar ophthalmic solutions, indicating a potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Provided written informed consent prior to any study-related procedures. * Are between 30 and 80 years of age. * Have a history of dry eye disease in both eyes. * Have been using artificial tears within 30 days of the screening visit * Have an Eye dryness score ≥50 (0-100 point VAS) * Have ongoing dry eye disease in the same eye or both eyes, as defined by all of the following criteria in the study eye and the same eye at Visit 1 and Visit 2: 1) total CFS (tCFS) score ≥6; 2) any subregion CS score ≥2.5; 3) Schirmer score (without anesthesia) ≥1 and ≤7 mm/5 min. * Have a BCVA in the study eye of ≥4.3 (Standard for Logarithmic Visual Acuity Charts, 5-mark record). Exclusion Criteria: * Have a known hypersensitivity or contraindication to the IP or components of IP. * Have history of uncontrolled glaucoma, IOP over 21 mmHg in either eye at the screening visit or are being treated with eye drops for glaucoma in the study eye. Or the subject has had laser or surgery for glaucoma in the study eye within 90 days of the study. * Woman of childbearing potential (WOCP) who are pregnant, lactating, or preparing for pregnant.
Where it's running
-
Eye & Ent Hospital of Fudan University
Shanghai, Shanghai Municipality, China Recruiting
Study contacts
- Principal investigator: Xinghuai Sun — Eye & ENT Hospital of Fudan University
- Study coordinator: Caroline Lu
- Email: caroline.lu@vivavisionbio.com
- Phone: 86-18816562189
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Lacrifill to Help Prevent Post-Curgery Dry Eye After Cataract Surgery
This study tests Lacrifill to see if it helps prevent dry eye symptoms after unilateral cataract surgery.
-
Tear-Fluid Stability Testing with iTrace, BOSA, OPD-Scan III, and IDRA for Dry Eye
A Phase 4 study tests whether four eye devices can detect tear film stability in adults with normal tear film.
-
OT202 1% eye drops for moderate to severe dry eye
This phase 3 study tests whether 1% OT202 eye drops help people with moderate to severe dry eye better than a placebo.
-
Tyrvaya Nasal Spray for Comfort in Contact Lens Wearers
This study tests whether using Tyrvaya twice daily can improve comfort for adults who wear soft contact lenses and have dry eye symptoms.
-
Long-term effects of Acoltremon vs. control in dry eye disease
This study tests whether Acoltremon eye drops help people with dry eye over a year compared with a preservative-free artificial tear, at a single center.
-
Effect of Dry Eye Treatment on Corneal Astigmatism Measurements
This study tests whether short-term treatment for dry eye changes how consistently three devices measure corneal astigmatism in people preparing for cataract surgery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.